New insights into PTEN regulation mechanisms and its potential function in targeted therapies

Biomedicine and Pharmacotherapy

Volumn 66, Issue 7, 2012, Pages 485-490

  Zhang, Peng ^a   Chen, Jin hua ^a   Guo, Xiu li ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Post translational regulation; PTEN; Therapy target; Transcriptional regulation

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; EPIDERMAL GROWTH FACTOR; ESTRADIOL; FOLLITROPIN; HISTONE ACETYLTRANSFERASE; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN C JUN; PROTEIN KINASE B; PROTEIN P53; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA;

ACETYLATION; ANTIPROLIFERATIVE ACTIVITY; CARCINOGENESIS; DIABETES MELLITUS; ENZYME METABOLISM; ENZYME PHOSPHORYLATION; HUMAN; NEOPLASM; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

DIABETES MELLITUS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; OBESITY; PHOSPHORYLATION; PTEN PHOSPHOHYDROLASE;

EID: 84867335291     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.04.004     Document Type: Review

References (67)

1. Waite K.A., Eng C. Protean PTEN: form and function. Am J Hum Genet 2002, 70(4):829-844.
2. Chu E.C., Tarnawski A.S. PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monit 2004, 10(10):235-241.
3. Gericke A., Munson M., Ross A.H. Regulation of the PTEN phosphatase. Gene 2006, 374:1-9.
4. Campbell R.B., Liu F., Ross A.H. Allosteric activation of PTEN phosphatase by phosphatidylinositol 4,5-bisphosphate. J Biol Chem 2003, 278(36):33617-33620.
5. Redfern R.E., Redfern D., Furgason M.L., Munson M., Ross A.H., Gericke A. PTEN phosphatase selectively binds phosphoinositides and undergoes structural changes. Biochemistry 2008, 47(7):2162-2171.
6. Tolkacheva T., Boddapati M., Sanfiz A., Tsuchida K., Kimmelman A.C., Chan A.M. Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. Cancer Res 2001, 61(13):4985-4989.
7. Yamada K.M., Araki M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci 2001, 114(13):2375-2382.
8. Hamada K., Sasaki T., Koni P.A., Natsui M., Kishimoto H., Sasaki J., et al. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 2005, 19(17):2054-2065.
9. Tamguney T., Stokoe D. New insights into PTEN. J Cell Sci 2007, 120(23):4071-4079.
10. Patel L., Pass I., Coxon P., Downes C.P., Smith S.A., Macphee C.H. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol 2001, 11(10):764-768.
11. Farrow B., Evers B.M. Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. Biochem Biophys Res Commun 2003, 301(1):50-53.
12. Zhang W., Wu N., Li Z., Wang L., Jin J., Zha X.L. PPARgamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404. Cancer Biol Ther 2006, 5(8):1008-1014.
13. Shen Y.H., Zhang L., Gan Y., Wang X., Wang J., LeMaire S.A., et al. Up-regulation of PTEN (phosphatase and tensin homolog deleted on chromosome ten mediates p38 MAPK stress signal-induced inhibition of insulin signaling. A cross-talk between stress signaling and insulin signaling in resistin-treated human endothelial cells. J Biol Chem 2006, 281(12):7727-7736.
14. Wang J., Ouyang W., Li J., Wei L., Ma Q., Zhang Z., et al. Loss of tumor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor kappaB induced by UV radiation. Cancer Res 2005, 65(15):6601-6611.
15. Ferraro B., Bepler G., Sharma S., Cantor A., Haura E.B. EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer. J Clin Oncol 2005, 23(9):1921-1926.
16. Okamura H., Yoshida K., Morimoto H., Haneji T.P.T.E.N. expression elicited by EGR-1 transcription factor in calyculin A-induced apoptotic cells. J Cell Biochem 2005, 94(1):117-125.
17. Su L., Cheng H., Sampaio A.V., Nielsen T.O., Underhill T.M. EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor. Oncogene 2010, 29(30):4352-4361.
18. Baron V., Adamson E.D., Calogero A., Ragona G., Mercola D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther 2006, 13(2):115-124.
19. Andjelkovic T., Bankovic J., Stojsic J., Milinkovic V., Podolski-Renic A., Ruzdijic S., et al. Coalterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients. Transl Res 2011, 157(1):19-28.
20. Stambolic V., MacPherson D., Sas D., Lin Y., Snow B., Jang Y., et al. Regulation of PTEN transcription by p53. Mol Cell 2001, 8(2):317-325.
21. Poon J.S., Eves R., Mak A.S. Both lipid- and protein-phosphatase activities of PTEN contribute to the p53-PTEN anti-invasion pathway. Cell Cycle 2010, 9(22):4450-4454.
22. Anderson K., Nordquist K.A., Gao X., Hicks K.C., Zhai B., Gygi S.P., et al. Regulation of cellular levels of sprouty2 protein by prolyl hydroxylase domain and von hippel-lindau proteins. J Biol Chem 2011, 286(49):42027-42036.
23. Edwin F., Singh R., Endersby R., Baker S.J., Patel T.B. The tumor suppressor PTEN is necessary for human Sprouty 2-mediated inhibition of cell proliferation. J Biol Chem 2006, 281(8):4816-4822.
24. Lecureuil C., Kara E., Guillou F., Monniaux D., Crepieux P. Does FSH signaling have a gender?. Med Sci (Paris) 2007, 23(1):5-80.
25. Dupont J., Musnier A., Decourtye J., Boulo T., Lecureuil C., Guillou H., et al. FSH-stimulated PTEN activity accounts for the lack of FSH mitogenic effect in prepubertal rat Sertoli cells. Mol Cell Endocrinol 2007, 315:271-276.
26. Kitade Y., Akao Y. MicroRNAs and their therapeutic potential for human diseases: microRNAs, miR-143 and -145, function as anti-oncomirs and the application of chemically modified miR-143 as an anti-cancer drug. J Pharmacol Sci 2010, 114(3):276-280.
27. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297.
28. Liu L., Jiang Y., Zhang H., Greenlee A.R., Han Z. Overexpressed miR-494 down-regulates PTEN gene expression in cells transformed by anti-benzo(a)pyrene-trans-7,8-dihydrodiol-9,10-epoxide. Life Sci 2010, 86:192-198.
29. Gong C., Yao Y., Wang Y., Liu B., Wu W., Chen J., et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 2010, 286(21):19127-19137.
30. Zhang H., Zhao X., Liu S., Li J., Wen Z., Li M. 17betaE2 promotes cell proliferation in endometriosis by decreasing PTEN via NFkappaB-dependent pathway. Mol Cell Endocrinol 2010, 317(1-2):31-43.
31. Xia D., Srinivas H., Ahn Y.H., Sethi G., Sheng X., Yung W.K., et al. Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway. J Biol Chem 2007, 282(6):3507-3519.
32. Hettinger K., Vikhanskaya F., Poh M.K., Lee M.K., de Belle I., Zhang J.T., et al. c-Jun promotes cellular survival by suppression of PTEN. Cell Death Differ 2007, 14(2):218-229.
33. Ma J., Sawai H., Matsuo Y., Ochi N., Yasuda A., Takahashi H., et al. IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells. J Surg Res 2010, 160(1):90-101.
34. Chow J.Y., Dong H., Quach K.T., Van Nguyen P.N., Chen K., Carethers J.M. TGF-beta mediates PTEN suppression and cell motility through calcium-dependent PKC-alpha activation in pancreatic cancer cells. Am J Physiol Gastrointest Liver Physiol 2008, 294(4):899-905.
35. Chow J.Y., Quach K.T., Cabrera B.L., Cabral J.A., Beck S.E., Carethers J.M. RAS/ERK modulates TGFbeta-regulated PTEN expression in human pancreatic adenocarcinoma cells. Carcinogenesis 2007, 28(11):2321-2327.
36. Miller S.J., Lou D.Y., Seldin D.C., Lane W.S., Neel B.G. Direct identification of PTEN phosphorylation sites. FEBS Lett 2002, 528:145-153.
37. Maccario H., Perera N.M., Davidson L., Downes C.P., Leslie N. PTEN is destabilized by phosphorylation on Thr366. Biochem J 2007, 405(3):439-444.
38. Vazquez F., Ramaswamy S., Nakamura N., Sellers W.R. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 2000, 20(14):5010-5018.
39. Silva A., Jotta P.Y., Silveira A.B., Ribeiro D., Brandalise S.R., Yunes J.A., et al. Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors. Haematologica 2009, 95(4):674-678.
40. Xu D., Yao Y., Jiang X., Lu L., Dai W. Regulation of PTEN stability and activity by Plk3. J Biol Chem 2010, 285(51):39935-39942.
41. Torres J., Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem 2001, 276(2):993-998.
42. Al-Khouri A.M., Ma Y., Togo S.H., Williams S., Mustelin T. Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem 2005, 280(42):35195-35202.
43. Yim J.H., Kim Y.J., Ko J.H., Cho Y.E., Kim S.M., Kim J.Y., et al. The putative tumor suppressor gene GLTSCR2 induces PTEN-modulated cell death. Cell Death Differ 2007, 14(11):1872-1879.
44. Okahara F., Ikawa H., Kanaho Y., Maehama T. Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein. J Biol Chem 2004, 279(44):45300-45303.
45. Orloff M.S., Eng C. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. Oncogene 2008, 27(41):5387-5397.
46. Vemula S., Shi J., Hanneman P., Wei L., Kapur R. ROCK1 functions as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. Blood 2010, 115(9):1785-1796.
47. Gajewski J.E., Bird M.J., Crowhurst M.O., Sio-Seng Lio D., Liu J., Wettenhall R.E., et al. Expression, generation, and purification of unphosphorylated and phospho-Ser-380/Thr-382/Thr-383 form of recombinant PTEN phosphatase. Protein Expr Purif 2007, 55(2):334-342.
48. Ross S.H., Lindsay Y., Safrany S.T., Lorenzo O., Villa F., Toth R., et al. Differential redox regulation within the PTP superfamily. Cell Signal 2007, 19(7):1521-1530.
49. Tonks N.K. Redox redux: revisiting PTPs and the control of cell signaling. Cell 2005, 121(5):667-670.
50. Cho S.H., Lee C.H., Ahn Y., Kim H., Ahn C.Y., Yang K.S., et al. Redox regulation of PTEN and protein tyrosine phosphatases in H(2)O(2) mediated cell signaling. FEBS Lett 2004, 560:7-13.
51. Silva A., Yunes J.A., Cardoso B.A., Martins L.R., Jotta P.Y., Abecasis M., et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008, 118(11):3762-3774.
52. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation?. EMBO J 2000, 19(6):1176-1179.
53. Okumura K., Zhao M., Depinho R.A., Furnari F.B., Cavenee W.K. Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc Natl Acad Sci U S A 2005, 102(8):2703-2706.
54. Duclot F., Jacquet C., Gongora C., Maurice T. Alteration of working memory but not in anxiety or stress response in p300/CBP associated factor (PCAF) histone acetylase knockout mice bred on a C57BL/6 background. Neurosci Lett 2010, 475(3):179-183.
55. Okumura K., Mendoza M., Bachoo R.M., DePinho R.A., Cavenee W.K., Furnari F.B. PCAF modulates PTEN activity. J Biol Chem 2006, 281(36):26562-26568.
56. Ikenoue T., Inoki K., Zhao B., Guan K.L. PTEN acetylation modulates its interaction with PDZ domain. Cancer Res 2008, 68(17):6908-6912.
57. Pan L., Lu J., Wang X., Han L., Zhang Y., Han S., et al. Histone deacetylase inhibitor trichostatin a potentiates doxorubicin-induced apoptosis by up-regulating PTEN expression. Cancer 2007, 109(8):1676-1688.
58. Kim S.K., Yang J.W., Kim M.R., Roh S.H., Kim H.G., Lee K.Y., et al. Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells. Free Radic Biol Med 2008, 45(4):537-546.
59. Phuong N.T., Kim S.K., Lim S.C., Kim H.S., Kim T.H., Lee K.Y., et al. Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells. Breast Cancer Res Treat 2011, 130(1):73-83.
60. Pathiraja T.N., Shetty P.B., Jelinek J., He R., Hartmaier R., Margossian A.L., et al. Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res 2011, 17(12):4177-4186.
61. Carver B.S., Tran J., Gopalan A., Chen Z., Shaikh S., Carracedo A., et al. expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009, 41(5):619-624.
62. Chetram M.A., Don-Salu-Hewage A.S., Hinton C.V. ROS enhances CXCR4-mediated functions through inactivation of PTEN in prostate cancer cells. Biochem Biophys Res Commun 2011, 410(2):195-200.
63. Mulholland D.J., Tran L.M., Li Y., Cai H., Morim A., Wang S., et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 2011, 19(6):792-804.
64. Peyrou M., Bourgoin L., Foti M. PTEN in liver diseases and cancer. World J Gastroenterol 2010, 16(37):4627-4633.
65. Yamamoto Y., Maeshima Y., Kitayama H., Kitamura S., Takazawa Y., Sugiyama H., et al. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 2004, 53(7):1831-1840.
66. Mahimainathan L., Das F., Venkatesan B., Choudhury G.G. Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN. Diabetes 2006, 55(7):2115-2125.
67. Kato M., Putta S., Wang M., Yuan H., Lanting L., Nair I., et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 2009, 11(7):881-889.